On Friday, the office of the mayor of Chicago announced that electronic cigarette manufacturer Juul Labs Inc. has reached a $23.8 million settlement agreement with the city of Chicago. The city had accused Juul Labs of deceptive marketing and selling e-cigarettes to underage users. The settlement is equivalent to 164 million yuan.
According to a report by Reuters, this electronic cigarette company is currently facing thousands of lawsuits across the United States, which involve its marketing practices and contributing to the increase in youth smoking rates.
In the settlement agreement, Chicago officials stated that Juul had denied any improper behavior or responsibility related to the design, manufacturing, production, advertising, marketing, distribution, sale, use, and performance of their product.
According to the settlement agreement, the company has agreed to pay $2.8 million (equivalent to $19.34 million under the contract) to the city within 30 days of the agreement's implementation.
The office of the Mayor of Chicago has announced that the city is set to receive an additional $21 million later this year as part of its current plans, with the possibility of further court settlements of up to $750,000.
Related reading:
Two school districts in the state of Florida have reached a $10 million settlement with Juul.
Orange County in the United States is set to purchase electronic cigarette detectors after reaching a settlement of $5.4 million with Juul.
Reference:
Juul Labs has reached a settlement of $24 million with the city of Chicago.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
